SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SMS Pharmaceuticals - Quaterly Results

24 May 2023 Evaluate
The Total revenue for the quarter ended March 2023 of  Rs. 1494.26 millions grew by 145.29% from Rs. 609.19 millions.The Net Profit of the company registered a slight decline of -10.86% to Rs. 80.75  millions from Rs. 90.59 millions. Operating profit Margin for the quarter ended March 2023 improved to 245.03% as compared to -38.61% of corresponding quarter ended March 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 1494.26 609.19 145.29 5220.51 5198.74 0.42 5220.51 5198.74 0.42
Other Income 12.56 4.26 194.84 48.86 51.98 -6.00 48.86 51.98 -6.00
PBIDT 245.03 -38.61 -734.63 595.90 1196.83 -50.21 595.90 1196.83 -50.21
Interest 58.85 43.41 35.57 219.15 188.75 16.11 219.15 188.75 16.11
PBDT 186.18 -82.02 -326.99 376.75 1008.08 -62.63 376.75 1008.08 -62.63
Depreciation 79.75 79.72 0.04 321.25 321.52 -0.08 321.25 321.52 -0.08
PBT 106.43 -161.74 -165.80 55.50 686.56 -91.92 55.50 686.56 -91.92
TAX 25.68 -252.33 -110.18 14.65 6.18 137.06 14.65 6.18 137.06
Deferred Tax 25.13 -221.54 -111.34 14.69 -143.02 -110.27 14.69 -143.02 -110.27
PAT 80.75 90.59 -10.86 40.85 680.38 -94.00 40.85 680.38 -94.00
Equity 84.65 84.65 0.00 84.65 84.65 0.00 84.65 84.65 0.00
PBIDTM(%) 16.40 -6.34 -358.73 11.41 23.02 -50.42 11.41 23.02 -50.42

SMS Pharmaceuticals Share Price

427.60 3.45 (0.81%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×